System models

CMS on Wednesday released a concluding rule that establishes standards towards electronic prescribing guardianship the Medicare prescription drug benefit, CQ HealthBeat reports.

The rule establishes standards in the interest of the electronic transmission of bumf of the medications covered under the Medicare medicament drug plans of beneficiaries and the availability of generic versions of those treatments. The standards allow physicians and other well-being care providers, as well as pharmacies and Medicare prescription drug plan sponsors, to share information about medications taken by beneficiaries. In addition, the standards allow pharmacies to inform physicians and other providers when patients obtain their prescriptions. The rule does not require physicians, pharmacies and other providers to adopt e-prescribing to participate in Medicare.

HHS Secretary Mike Leavitt said, “Establishing standards object of e-prescribing under Medicare’s prescription numb program hand down alleviate pave the way for widespread adoption of e-prescribing throughout the medical community,” adding, “Broader use of e-prescribing offers beneficiaries safer and more competent care at move costs.”

Supporters hope that the rule ordain restraint to passage of a bill (S 2408) that would require physicians who participate in Medicare to embrace e-prescribing by 2011. Emblem Merritt, president and CEO of the Pharmaceutical Tribulation Government Association, said, “The time is now fit e-prescribing in Medicare,” adding, “Today will be remembered as a major step in the drive during well-being IT reform” (Carey, CQ HealthBeat, 4/2).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Constantly Health Rule Write up, search the archives, or sign up also in behalf of email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Condition Principles Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Extraction Foundation© 2005 Advisory Board Guests and Kaiser Relations Institution. All rights reserved.

Identifying an anthrax attack in a patient has been to the nth degree difficult for doctors because the symptoms are quite similar to those of a bad invalid of acute respiratory infection, such as pneumonia.

Researchers from the Northwestern Univeristy of Chicago have identified a unique set of symptoms which point to Anthrax.

Demetrios Kyriacou, team leader, said “We develop on the cards clinical characteristic symptoms and laboratory findings will help tell the difference between inhaled anthrax and other respiratory diseases.”

Kyriacou said that if a physician notices the following he/she should seriously regard anthrax inhalation (especially the pre-eminent two below):

– Swollen caddy

– Fluid in the chest cavity

– Nausea

– Vomiting

– Altered view state (confusion)

Kyriacou suggested that if a doctor sees three patients with those symptoms then a alarming terrorist attack has probably taken place.

Experts stipulate that early detection of a arsonist attack makes an goods response much easier to carry out.

Kyriacou and his team looked at (read the records) 47 cases of anthrax inhalation as a follow of an anthrax attack (not experiments or accidents). They compared the figures on these people against a control group of 376 people who had ILI (influenza-similarly to illness).

The anthrax patients were 23 times more likely to have fluid in the casket cavity and a proud chest (mediastinal widening) than those in the control group.

The team also set that the anthrax patients were much more likely to exposure nausea, vomiting and confusion.

Bone marrow lesions in the knee, a induce of wound in patients with knee osteoarthritis, may be hereditary. A study published today in the journal Arthritis Research & Therapy reveals that there is a significant genetic component to the occurrence and beastliness of bone marrow lesions in the tibia and femur. The study also shows that bone marrow lesions are more common in men and increase with duration and force.

Guangju Zhai, from St Thomas’ Clinic, London, UK and colleagues from institutions in Australia intentional 115 siblings from 48 families with a history of osteoarthritis. Zhai et al. used magnetic resonance imaging (MRI) to assess bone marrow lesions in the subjects. The authors then adapted the heritability estimates – or the bounds to which they are hereditary – in support of bone marrow lesions in lateral and medial tibia and femur.

The results of Zhai et al.’s study exposition that the heritability estimate was 99% for the sway of bone marrow lesions in both lateral and medial compartments of the bones. The heritability estimates for the monasticism of bone marrow lesions are 53% destined for lateral bones and 65% for medial bones, after calibrating for age, coition, height, weight, muscle strength, knee wound and knee alignment.

The authors conclude that further studies to identify the gene(s) front-office for bone marrow lesions may resist in the obstructing and running of knee exertion in osteoarthritis, the most common comprise of arthritis.

Surrounding the BIOMED CENTRAL LIMITED

BioMed Primary is an independent publishing house committed to providing reflex free access to match-reviewed biomedical research.

BIOMED SIGNIFICANT LIMITED
Middlesex House
34-42 Cleveland Street
London
W1T 4LB

info@biomedcentral.com
http://www.biomedcentral.com

Two MRC funded-scientists have been awarded a Royal Medal by the Duke Society. The annual awards are made to researchers in recognition of the discerning implications their findings oblige had for others working in their fields. Sir Alan Fersht, Director of the MRC Centre exchange for Protein Engineering at Cambridge University, and Sir Philip Cohen Headman of the Medical Inspection Council’s Protein Phosphorylation Segment in Dundee are the two medal winners.

Sir Alan Fersht FRS FMedSci, who is also the Herchel Smith Professor of Coherent Chemistry at Cambridge University, has been awarded the Royal Medal A payment his seminal position in protein engineering, which he has developed into a fundamental tool in enzyme breakdown and the problem of protein folding.

Sir Philip Cohen FRS FRSE, who is also a Research Professor at the University of Dundee and Overseer-Designate of the newly established Scottish Initiate for Room Signalling, has been awarded the Noblewoman Medal B for his worst contribution to the handle on of the place of protein phosphorylation in apartment proclamation.

The Regal Medal A medallists are chosen each year by the Physical Sciences Awards Council and the Royal Medal B medallists by the Biological Sciences Awards Committee. The two committees are made up of Fellows of the Society.

On hearing of his award, Professor Cohen said:

“I am enchantee ‘ to from received this honour which is only awarded to one scientist in the UK biological sciences community each year. Coming so ultimately after my recent vote to the US National Academy of Sciences, this has been relatively a year for the MRC Protein Phosphorylation Module at Dundee – Dario Alessi was elected a Associate of The Royal Society, John Incite received the Colworth Medal of the Biochemical Society and Kei Sakamoto was honoured with the Girlish Investigator Give of the American Physiological Society.”

Sir Alan commented:

”The greatest excite in favour of me is to have been awarded the same medal as my precise heroes from the MRC Laboratory of Molecular Biology in recent years as soundly as notable scientists of yore, such as Charles Darwin, Humphrey Davy and Michael Faraday, and so bathe in a just a little of their reflected celebrity.”

In addition to the Majestic Medal Sir Alan was recently elected to the American Thoughtful Society.

Only three Stately Medals are awarded each year, for the most important contributions to the advancement of natural knowledge: one in the medic sciences, one in biological sciences, and the third in applied sciences. The Nobel prize winners Frederick Sanger, Sydney Brenner, Max Perutz and Francis Crick, among others, have all received Splendid Medals during the medal’s rich history.

Medical Investigating Synod

The United States suffers from an acute shortage of kidneys due to the fact that transplant, with 73,000 people waiting for deceased donors to make organs nearby.

Allowing compensation for donors, an idea that has allowed Iran to completely eliminate its waiting lists, would help solve this problem, reports a new study by the Cato Institute.

In “Organ Sales and Moral Travails,” Benjamin E. Hippen, MD, transplant nephrologist, shows that Iran’s system of compensated donation has effectively provided the organs needed for transplant. “Iran is the only country that legally permits kidney vending,” he writes. “The waiting list for kidneys was eliminated in 1999, 11 years after the legalization of organ vending, and for the past 8 years, Iran has had no waiting list for kidneys.”

Concerns about the negative impacts of offering financial incentives for kidney donation naturally arise. Hippen reports that Iran has addressed this problem by putting a non-profit intermediary between potential kidney vendors and patients in need. “Separating the role of identifying vendors from the role of evaluating their medical, surgical, and psychological suitability permits transplant professionals to avoid confusing judgment on a vendor’s candidacy with various financial and professional incentives to perform more transplants,” Hippen writes.

Though the Iranian system is not perfect, it offers lessons that would be of value to American policy makers seeking to reduce the United States’ tragic organ shortage by setting up markets. “A review of 20 years of experience with a living organ vendor system in Iran reveals successes, deficiencies, and ambiguities,” Hippen concludes. “If the discussion of kidney markets in this country can progress beyond preconceptions as to what can and cannot work, in Iran or elsewhere, to an examination of the example of the Iran based on the evidence, that will be a significant step in the right direction.”

http://www.cato.org/

An international team of researchers has discovered what promises to be the on-off birch behind several major diseases. In the ahead of online edition of today’s Properties Nostrum, scientists from Sainte-Justine Hospital Experiment with Center, the Université de Montréal and the Institut national de la santé et de la recherche médicale (INSERM) in France report how the GPR91 receptor contributes to activate unchecked vascular flowering that causes mirage loss in common blinding diseases. These findings could also have wide-ranging and positive implications for mastermind tissue regeneration.

While investigating the molecular mechanisms that supremacy to vision sacrifice, the analyse work together uncovered that the GPR91 receptor can mediate irregular vascular extension that is responsible for some of the main causes of blindness in the industrial Terra: retinopathy of prematurity in infants, diabetic retinopathy in adults (vision impoverishment or blindness that affects up to 90 percent of diabetics) or age-related macular degeneration in seniors (central welcome sight loss).

“We ground that GPR91 is a master regulator of blood vessel growth, which upon enhanced activation leads to the unchecked and anarchic spread of vascular networks, which is the hallmark of retinopathies. This untrammelled overgrowth can ultimately producer the retina to detach and a living soul to lose their sight,” says Dr. Mike Przemyslaw Sapieha, the study’s potential originator and a scientist at the Sainte-Justine Clinic Reserch Center and the Université de Montréal.

“With the naming of GPR91 as a key player in this cancer take care of, we can remind well-advanced in treacherous treatments that cube the receptor and consequently break vision loss,” adds Dr. Sapieha. “Inhibition of GPR91 has a significant therapeutic potential to halt these blinding diseases.”

GPR91 to save neurons

The team’s review also provides promise that the GPR91 receptor could protect neurons. “Neurons are key sensors in retina oxygenation and serve as key players in the repair process of the retina,” explains Dr. Sylvain Chemtob, director of the study and a neonatal researcher at the Sainte-Justine Hospital Exploration Center and professor at the
Université de Montréal’s Department of Pediatrics, Ophthalmology, Pharmacology and the Denomination of Optometry.

“Given the similarities between the retina and the brain, we can conjure up applying our findings in retina to the brain,” says Dr. Chemtob. “Activation of the GPR91 receptor could be salubrious in helping salvage neurons in damaged brain mass in stroke or head injury victims.”

GPR91 to stop cancer growth

This retreat is the cardinal to examine the not on target-ranging implications of GPR91 and to investigate how the receptor, which is present in neurons, responds to stresses and reconcile when in its oxygenation state is compromised. “This is a new concept in vascular biology,” says Dr. Sapieha, noting it is conceivable that interfering with the GPR91 receptor could be used to stop cancer growth. “If you stop GPR91 from allowing blood vessels to expand and afford a tumour with nutrients and oxygen, one can significantly hamper intumescence of the cancer.”

While these promising investigations on GPR91 were conducted in animals, the receptor is also found in humans, and Dr. Chemtob surmises that extension of the research to human clinical investigations could be in three to fours years. “We surmise these findings to have planned an enormous impact,” he says.

About the library

“The succinate receptor GPR91 in neurons plays a chief role in retinal angiogenesis,” published in Nature Nostrum, was authored by Mike Przemyslaw Sapieha, Sylvain Chemtob, Mirna Sirinyan, David Hamel, Karine Zaniolo, Jean-Sebastien Joyal, Jean-Claude Honoré, Christian Beausejour, Grant Mitchell, Gregor Andelfinger, Sophie Tremblay, Martin Leduc, Lenka Rihakova, Pierre Durable and Adriana Di Polo (Sainte-Justine Hospital Research Center and Université de Montréal, Quebec, Canada); Daya R Varma and Orval Mamer (McGill University, Montreal, Quebec, Canada); Jang-Hyeon Cho, William H. Klein and Xiuqian Mu (University of Texas MD Anderson Cancer Center, Houston, TX, U.S.A.); Florian Sennlaub and Elsa Kermorvant-Duchemin (Inserm U872, Paris, France).

Partners in research

This study was funded through grants from the Canadian Institutes of Health Research, the Heart and Stroke Foundation of Quebec, the Fonds de la recherche en santé du Québec, the Heart and Stroke Foundation of Canada, the Step of Dimes Creation Defects Foundation, the Robert A. Welch Foundation and the Substructure Fighting Blindness.

On the Web

About the journal Countryside Medicine
Involving the Sainte-Justine Sickbay Inspection Center
About the Université de Montréal: www.umontreal.ca/english/index.htm
Fro McGill University
About the University of Texas MD Anderson Cancer Center
About Inserm

Hallmarks of autism are characteristic behaviors – humdrum motions, problems interacting with others, impaired communication abilities – that develop in extensively different combinations and degrees of painfulness among those who have the demand.

But how those behaviors change as individuals progress through adolescence and adulthood has, until now, never been fully scientifically documented. In a new study, published in the September Journal of Autism and Developmental Disorders, researchers have found that symptoms can improve with age.

“On average, people are getting better,” says Paul T. Shattuck, an assistant professor of social work at Washington University in St. Louis who worked on the study as a graduate student and post-doctoral fellow at the University of Wisconsin-Madison’s Waisman Center and is the first author of the paper. “It is a hopeful finding, but the fact remains that those with severe autism will depend on others for their everyday needs and care for the rest of their lives.”

Autism is a widespread condition in the United States, affecting an estimated one in 150 children and an unknown number of adults.

The new publication is part of a groundbreaking longitudinal study of more than 400 adolescents and adults with autism and their families led by Marsha Mailick Seltzer, a Wisconsin professor of social work and the director of the UW-Madison Waisman Center. “This project is one of the largest long-term studies of autism and it represents the collaborations of a team of researchers who together are investigating how autism changes across the life course,” Seltzer explains.

Half of the study’s participants are from Wisconsin and half are from Massachusetts. They were recruited from service agencies, schools and clinics. Every 18 months, parents in the study are interviewed in depth to assess changes in their child’s symptoms and behaviors.

The new paper reports on how behavior in 241 adolescents and adults, initially aged 10 to 52 years, changed over a five-year period. Although symptoms for many in the study remained stable, a significant proportion exhibited improvements in symptoms and maladaptive behaviors.

“For all major symptoms, the percentage of people who improved was always greater than the percentage who worsened,” Shattuck says. “If there was significant symptom change over time, it was always in the direction of improvement, though there was always a group in the middle that showed no change. The mean never went down.”

Like most people, individuals with developmental disabilities such as autism continue to grow and change over time, Shattuck explains: “Their development is not frozen in time and forever the same. That’s just not the case.”

The paper reported on changes in broad categories of typical autistic symptoms: impaired verbal and nonverbal communication, impaired social interaction, and repetitive behaviors. Within those broad categories, changes across 32 specific symptoms – ranging from reciprocal conversation and interest in people to compulsions and rituals – were measured. Also examined were broader maladaptive behaviors such as aggression and self-injury that are not specific to autism. Across all categories, the proportion of study participants who improved was larger than the proportion that worsened.

Of those in the study, 69 percent were also classified as having mental retardation.

“Not everyone on the autism spectrum is mentally retarded,” Shattuck says, “but being mentally retarded reduces the likelihood of improvement for many symptoms.”

Why some in the sample improved is being investigated as part of the ongoing study, according to Shattuck.

“Our study demonstrates that significant changes are occurring,” he explains. “But in terms of the underlying biological mechanisms, we don’t yet know what’s going on.”

http://www.wisc.edu/

The Bush charge on Thursday officially notified US organizations providing HIV/AIDS-related services in other countries that they must sign a pledge contradictory commercial sex work and sex trafficking to be considered for federal funding,… USA Today reports (Sternberg, USA Today, 6/10). The protocol stems from two 2003 laws, including an amendment to legislation (HR 1298) authorizing the President’s Emergency Plan for AIDS Contrast that prohibits funds from effective to any group or form that does not keep a policy “explicitly opposing prostitution and sex trafficking.” The policy originally applied only to overseas groups because the Department of Justice had constitutional not liable diction concerns in applying it to U.S. organizations. Regardless, DOJ in 2004 reversed itself and said that the administration could appropriate the rule to U.S. groups (Kaiser Daily HIV/AIDS Report, 2/28). The law was amended pattern year to exclude multinational groups, including the Pandemic Fund To Misunderstanding AIDS, Tuberculosis and Malaria and U.N. agencies, according to USA Today. Kent Hill, confidante administrator suited for global health at USAID, said the Bush administration is enforcing what is required in the 2003 laws. How, Ira Lupu, a constitutional law professor at George Washington University, said the pledge violates the constitutional pronto to free address for the organizations and their employees. “You’re asking (the organizations) in exchange for federal grants to limit their activities under the accede to, to sell off their rights to engage in politically committed expression in support of other activities,” Lupu said. Paul Zeitz, entirely of the Global AIDS Unity, said, “No one endorses played out and sex trafficking. We cannot stop AIDS if we lose the belief of people most at risk of HIV infection and undermine effective, lifesaving programs” (USA Today, 6/10).

“Reprinted with lenience from kaisernetwork.org kaisernetwork.org. You can landscape the undiminished Kaiser Daily HIV/AIDS Check in, search the archives, or sign up on email delivery at www.kaisernetwork.org/dailyreports/hiv.. The Kaiser Commonplace HIV/AIDS Report is published for the sake of kaisernetwork.org, a free service of The Henry J. Kaiser Family Bottom . © 2005 Advisory Board Company and Kaiser Blood Foundation. All rights dignified.

“I’m emptied and I don’t know what else to do.” That’s a ordinary refrain we hear from callers reaching out for elder care supporter. Being a caregiver in regard to our own parents is a role most of us are lunge into with no preparation and no warning. It might be a swift illness, an accidental fall, or the establish realization that a parent is experiencing dementia, not just forgetfulness.

As adult children of aging parents, most of us start out in crisis mode when something happens to our parents. We juggle caregiving along with all our own family and work responsibilities. We may reach out to siblings and other relatives for caregiving support, trying to cobble together coverage for our parent’s medical appointments, household chores and meals. So many people get stressed and burdened to the breaking point before turning to outside help.

My wife Margot and I founded Good Company Senior Care based on our experiences caring for sick and elderly family members. We wanted to help seniors live safely and comfortably in their own homes as long as possible. Just as importantly, we wanted to be a resource for people struggling to balance their own lives with the ever-growing demands of caregiving for elderly loved ones.

As a caregiver you must ask for help. The stress of going it alone is dangerous to your health. A reputable senior care company can help you organize a care plan and tap into local community resources available to help you.

Here are just a few of our suggestions for lifting the burden of caregiver stress:

1. Seek in-home care management advice. If you want to help your loved one live at home rather than moving to an assisted living facility or nursing home, reach out to a trusted in-home senior care organization for help creating a care plan. Many organizations and private companies will give you advice and guidance at no cost. Non-medical home health care agencies like ours will help you connect with any and all available community resources. We can also help you look at your financial options in term of insurance, Medicare and subsidies, depending on your senior’s income level.

2. Take care of yourself first. You know that warning on airplanes about putting on your own oxygen mask before helping others? Keep that in mind when it comes to caregiving. When you’re stressed to the breaking point, you’re far less able to be useful and emotionally present for your loved one. Take breaks from caregiving, eat balanced meals and take time to exercise, sleep, and talk with friends. Everyone struggles with guilt, worry and the feeling that we’re not doing enough. Talk with others in similar situations and consider counseling for yourself and/or your family.

3. Seek out support groups – in person or online. There are excellent, helpful forums and support groups online and in many local communities for families of every type of patient. Whether your loved one is suffering from dementia, Alzheimer’s, cancer, stroke or just the frailty that comes with aging, there is a group to help you. Research shows that people who participate in support groups have lower rates of stress, guilt, anxiety and depression. Support group participants also become much better informed about outside resources and specialized expertise.

4. Learn about assistive technology options. There are a number of technologies to make sure your elderly parent or loved one is safe when home alone. Emergency alert bracelets and pendants, GPS tracking for wandering, remote video surveillance, tele-homecare, sensory augmentation and all sorts of assistive devices can help the elderly and disabled cope on their own. An in-home care agency like hours can offer advice and share our experience with some of these options.

5. Find out about long-term care insurance options. Having a good long-term care insurance policy can make a tremendous difference in the quality of in-home care you can afford for your elderly parent or loved one. If one or both of your parents is still healthy, look into the options. There are also useful strategies using a reverse mortgage to buy long-term care insurance. You should also consider insurance for yourself so when you need caregiving services someday, you’ll have more choices.

These are just a few of the suggestions we share with the families of the seniors we serve. To learn more about in-home senior care options, dementia care, caregiver stress, non-medical home care, and all aspects of elder care, please call us at 323-932-8700 and visit www.goodcoseniorcare.com.

Scientists at the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Investigation in London have identified how some bust cancers may adorn come of defiant to hormone treatments like tamoxifen.

The study, published in the February issue of the scientific journal Cancer Cell, shows for the first time that a protein called CDK10 is able to control the development of tamoxifen resistance in hormone sensitive breast cancer and has potentially important implications in the treatment of women with this form of the disease.

It is estimated that around 75% of breast tumours are hormone sensitive and use the female hormone oestrogen to grow. Tamoxifen and other anti-oestrogen drugs are a key treatment for women with this type of breast cancer because it reduces the ability of breast cancer cells to use oestrogen to grow, helping to prevent the disease spreading to other parts of the body or returning, and controlling tumours that have already spread. Tamoxifen can work extremely well for many women and has had a major impact on breast cancer survival. However, over time some patients’ tumours become resistant to tamoxifen.

Professor Alan Ashworth, Director of the Breakthrough Breast Cancer Research Centre, says; “Some hormone sensitive breast cancers will eventually become resistant to tamoxifen and this is the major reason why cancer may return. Research to understand why this happens is vital if we are to develop ways to overcome it for the benefit of patients.�

To develop a better understanding of how this might occur, Professor Ashworth, Dr Christopher Lord and colleagues at the Breakthrough Breast Cancer Research Centre used a sophisticated screening method to identify genes that, when suppressed, cause tamoxifen resistance. The researchers identified Cyclin-Dependent Kinase 10 (CDK10) as a critical component in determining cancer cells’ response to tamoxifen and other hormone therapies.

Importantly, the researchers also found that patients with low levels of CDK10 in their tumours were less likely to benefit from tamoxifen treatment – their cancers were more likely to return, and they tended not to survive for as long as women whose tumours produced higher levels of the molecule. They also uncovered important information on how this might occur – showing that a process called methylation may to be critical to ‘switching off’ CDK10 levels inside breast cancer cells.

Professor Alan Ashworth adds; “Drug resistance is a serious problem for women with breast cancer. It’s devastating for a patient to see their cancer return because of resistance, especially after enduring a long course of treatment and after a long period of remission. Through this work, we’ve identified some of the factors that control this effect and in the future we may be able to use this information to decide which treatments to give to patients to avoid resistance.�

This research is just one example of the groundbreaking work taking place at the Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research, Europe’s leading cancer research centre. One area of the centre’s work is to identify genetic changes that take place in breast cancer cells and use this knowledge to benefit patients in the clinic

Breakthrough Breast Cancer needs to raise at least £25 million each year for the next three years to support its vital research, campaigning and education work.

http://www.breakthrough.org.uk